<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54993</article-id><article-id pub-id-type="doi">10.7554/eLife.54993</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>NuRD subunit CHD4 regulates super-enhancer accessibility in Rhabdomyosarcoma and represents a general tumor dependency</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-171714"><name><surname>Marques</surname><given-names>Joana G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61926"><name><surname>Gryder</surname><given-names>Berkley E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171715"><name><surname>Pavlovic</surname><given-names>Blaz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171716"><name><surname>Chung</surname><given-names>Yeonjoo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171717"><name><surname>Ngo</surname><given-names>Quy A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171718"><name><surname>Frommelt</surname><given-names>Fabian</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3666-8005</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79596"><name><surname>Gstaiger</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171719"><name><surname>Song</surname><given-names>Young</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171720"><name><surname>Benischke</surname><given-names>Katharina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171721"><name><surname>Laubscher</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-171722"><name><surname>Wachtel</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-44111"><name><surname>Khan</surname><given-names>Javed</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-170559"><name><surname>Schäfer</surname><given-names>Beat W</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5988-2915</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Oncology</institution>, <institution>University Children's  Hospital</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff2"><institution content-type="dept">Oncogenomics Section, Center for Cancer Research, National Cancer Institute</institution>, <institution>Center for Cancer Research, National Institutes of Health</institution>, <addr-line><named-content content-type="city">Gaithersburg</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Institute of Molecular Systems Biology</institution>, <institution>ETH Zurich</institution>, <addr-line><named-content content-type="city">Zürich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff4"><institution content-type="dept">Department of Biology</institution>, <institution>Institute of Molecular Systems Biology</institution>, <addr-line><named-content content-type="city">Zurich</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff5"><institution content-type="dept">Genetics Branch</institution>, <institution>Center for Cancer Research, National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution content-type="dept">Pediatric Oncology Branch, Oncogenomics Section</institution>, <institution>Center for Cancer Research, National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-115383"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing editor</role><aff><institution>Van Andel Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>beat.schaefer@kispi.uzh.ch</email> (BS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>03</day><month>08</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e54993</elocation-id><history><date date-type="received"><day>08</day><month>01</month><year>2020</year></date><date date-type="accepted"><day>02</day><month>08</month><year>2020</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54993-v1.pdf"/><abstract><p>The NuRD complex subunit CHD4 is essential for fusion-positive rhabdomyosarcoma (FP-RMS) survival, but the mechanisms underlying this dependency are not understood. Here, a NuRD-specific CRISPR screen demonstrates that FP-RMS is particularly sensitive to CHD4 amongst the NuRD members. Mechanistically, NuRD complex containing CHD4 localizes to super-enhancers where CHD4 generates a chromatin architecture permissive for the binding of the tumor driver and fusion protein PAX3-FOXO1, allowing downstream transcription of its oncogenic program. Moreover, CHD4 depletion removes HDAC2 from the chromatin, leading to an increase and spread of histone acetylation, and prevents the positioning of RNA Polymerase 2 at promoters impeding transcription initiation. Strikingly, analysis of genome-wide cancer dependency databases identifies CHD4 as a general cancer vulnerability. Our findings describe CHD4, a classically defined repressor, as positive regulator of transcription and super-enhancer accessibility as well as establish this remodeler as an unexpected broad tumor susceptibility and promising drug target for cancer therapy.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Swiss National Science Foundation</institution></institution-wrap></funding-source><award-id>310030_156923 and 31003A_175558</award-id><principal-award-recipient><name><surname>Schäfer</surname><given-names>Beat W</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Cancer League Switzerland</institution></institution-wrap></funding-source><award-id>KLS-3868-02-2016</award-id><principal-award-recipient><name><surname>Schäfer</surname><given-names>Beat W</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Childhood Cancer Research Foundation Switzerland</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Schäfer</surname><given-names>Beat W</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Innovative Medicines Initiative ULTRA-DD</institution></institution-wrap></funding-source><award-id>115766</award-id><principal-award-recipient><name><surname>Frommelt</surname><given-names>Fabian</given-names></name><name><surname>Gstaiger</surname><given-names>Matthias</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The proteomics dataset supporting the conclusions of this article is available in the ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) repository with the dataset identifier PXD015231 (reviewer account: username - reviewer88401@ebi.ac.uk, password - mErsCglm). High-throughput ChIP-seq and DNase data are available through Gene Expression  Omnibus (GEO) Superseries with the accession number GSE140115. ChIP-seq data for H3K27ac, H3K27me3, H3K36me3, H3K4me1, H3K4me2, 587 H3K4me3, BRD4, CTCF, RAD21, HDAC2, and RNA Polymerase 2 as well as DNase I hypersensitivity data obtained for wildtype RH4 cells were previously published (Gryder et al., 2019b, 2017) and are available on the same data repository with the gene accession numbers GSE83728 and GSE116344. The RNA-seq data is available in the European Nucleotide Archive (ENA) with the accession number PRJEB34220 (reviewer account: username - Webin-53797, password  - kispiCHD42019).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Gryder BE</collab><collab>Wen X</collab><collab>Khan J</collab></person-group><year iso-8601-date="2019">2019</year><source>CHD4 regulates super-enhancer accessibility in fusion-positive rhabdomyosarcoma and is essential for tumor</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140115">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140115</ext-link><comment>Gene Expression Omnibus GSE140115</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Gryder BE</collab><collab>Yohe ME</collab><collab>Chou HC</collab><collab>Zhang X</collab><collab>Khan J</collab></person-group><year iso-8601-date="2017">2017</year><source>Epigenetic Lanscape and BRD4 Transcriptional Dependency of PAX3-FOXO1 Driven Rhabdomyosarcoma</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83728">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83728</ext-link><comment>Gene Expression Omnibus GSE83728</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Gryder BE</collab><collab>Wen X</collab><collab>Khan J</collab></person-group><year iso-8601-date="2019">2019</year><source>Selective Disruption of Core Regulatory Transcription [ChIP-seq]</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116344">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116344</ext-link><comment>Gene Expression Omnibus GSE116344</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-54993-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>